Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Clark Estates Inc. NY

Key Points

• Clark Estates Inc. NY reduced its stake in Lantheus Holdings, Inc. by 27.6%, retaining 25,237 shares currently valued at $2,463,000.
• Other institutional investors have increased their positions in Lantheus, with GAMMA Investing LLC boosting its stake by 12,517.1% during the same period.
• Lantheus reported earnings of $1.53 per share in its last quarter, missing estimates by $0.11, with a revenue of $372.76 million, slightly below expectations.

Clark Estates Inc. NY cut its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 27.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 25,237 shares of the medical equipment provider's stock after selling 9,637 shares during the period. Lantheus comprises approximately 0.5% of Clark Estates Inc. NY's portfolio, making the stock its 28th largest position. Clark Estates Inc. NY's holdings in Lantheus were worth $2,463,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. Signaturefd LLC lifted its stake in Lantheus by 36.5% in the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 116 shares during the last quarter. Hughes Financial Services LLC acquired a new position in shares of Lantheus in the 1st quarter valued at $81,000. UMB Bank n.a. raised its position in Lantheus by 68.2% in the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock valued at $92,000 after purchasing an additional 381 shares during the last quarter. Blue Trust Inc. raised its position in Lantheus by 117.7% in the 1st quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider's stock valued at $114,000 after purchasing an additional 633 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in Lantheus by 29.3% during the 1st quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider's stock worth $128,000 after purchasing an additional 298 shares during the period. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Trading Down 0.9%

Shares of NASDAQ:LNTH traded down $0.62 during trading on Friday, reaching $70.57. The stock had a trading volume of 943,059 shares, compared to its average volume of 1,017,600. Lantheus Holdings, Inc. has a fifty-two week low of $69.12 and a fifty-two week high of $118.21. The business has a fifty day moving average price of $77.65 and a 200-day moving average price of $87.98. The stock has a market cap of $4.88 billion, a P/E ratio of 20.05 and a beta of 0.14. The company has a quick ratio of 5.46, a current ratio of 5.74 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The business had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The firm's quarterly revenue was up .8% on a year-over-year basis. During the same period in the previous year, the business posted $1.69 earnings per share. As a group, analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

LNTH has been the topic of several recent research reports. Truist Financial dropped their price target on Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Wall Street Zen raised Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. William Blair restated a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th. Finally, B. Riley dropped their price target on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research report on Monday, June 23rd. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $131.20.

Insider Activity

In related news, Director Mary Anne Heino sold 26,066 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the transaction, the director owned 318,650 shares of the company's stock, valued at approximately $24,481,879.50. This represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.50% of the company's stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.